Home > Rheumatology > Risankizumab effective against refractory psoriatic arthritis

Risankizumab effective against refractory psoriatic arthritis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
BMJ Annals of the Rheumatic Diseases
Reuters Health - 17/01/2022 - Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. "Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse disease manifestations in patients who have not responded adequately to standard treatment," Dr. Lars Erik Kristensen of the University of Copenhagen and colleagues write in BMJ Annals of the Rheumatic Diseases. Current first-line treatments for PsA include non-steroidal anti-inflammatory drugs, local corticosteroid injections for musculoskeletal symptoms and topical therapies for psoriasis. For patients with an inadequate response or poor prognosis, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), antitumor necrosis factor therapy and other bio...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on